\BOOKMARK [0][-]{chapter*.2}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.3}{Acknowledgements}{}% 2
\BOOKMARK [0][-]{chapter*.4}{Declarations}{}% 3
\BOOKMARK [0][-]{chapter*.5}{Submitted Abstracts}{}% 4
\BOOKMARK [0][-]{chapter*.6}{Contents}{}% 5
\BOOKMARK [0][-]{chapter*.8}{List of Figures}{}% 6
\BOOKMARK [0][-]{chapter*.9}{List of Tables}{}% 7
\BOOKMARK [0][-]{chapter*.10}{Abbreviations}{}% 8
\BOOKMARK [0][-]{chapter.1}{Defining the genome-wide chromatin accessibility landscape and gene expression profile in psoriasis}{}% 9
\BOOKMARK [1][-]{section.1.1}{Introduction}{chapter.1}% 10
\BOOKMARK [2][-]{subsection.1.1.1}{The systemic and skin-specific manifestations of psoriasis}{section.1.1}% 11
\BOOKMARK [2][-]{subsection.1.1.2}{The personalised epigenome in disease}{section.1.1}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Transcriptional profiles in psoriasis}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.4}{Chromatin accessibility, gene expression and genetic variability}{section.1.1}% 14
\BOOKMARK [2][-]{subsection.1.1.5}{Fine-mapping using summary stats}{section.1.1}% 15
\BOOKMARK [1][-]{section.1.2}{Aims}{chapter.1}% 16
\BOOKMARK [1][-]{section.1.3}{Results}{chapter.1}% 17
\BOOKMARK [2][-]{subsection.1.3.1}{Psoriasis and healthy controls: cohort description and datasets}{section.1.3}% 18
\BOOKMARK [2][-]{subsection.1.3.2}{Investigation of psoriasis-specific changes in the enhancer mark H3K27ac in different peripheral blood immune cell populations}{section.1.3}% 19
\BOOKMARK [2][-]{subsection.1.3.3}{Identifying global changes in chromatin accessibility between psoriasis patients and healthy controls for different peripheral blood immune cell populations}{section.1.3}% 20
\BOOKMARK [2][-]{subsection.1.3.4}{Gene expression analysis in psoriasis circulating immune cells}{section.1.3}% 21
\BOOKMARK [2][-]{subsection.1.3.5}{RNA-seq in epidermis from psoriasis patients}{section.1.3}% 22
\BOOKMARK [2][-]{subsection.1.3.6}{Comparison of the systemic and tissue-specific gene expression signatures in psoriasis}{section.1.3}% 23
\BOOKMARK [2][-]{subsection.1.3.7}{Integration of chromatin accessibility and expression data in circulating immune cells}{section.1.3}% 24
\BOOKMARK [2][-]{subsection.1.3.8}{Fine-mapping of psoriasis GWAS loci and functional interpretation}{section.1.3}% 25
\BOOKMARK [2][-]{subsection.1.3.9}{Maximising genetic commonalities across chronic inflammatory diseases: locus 2p15}{section.1.3}% 26
\BOOKMARK [1][-]{section.1.4}{Discussion}{chapter.1}% 27
\BOOKMARK [2][-]{subsection.1.4.1}{Chromatin accessibility and H3K27ac landscape in psoriasis immune cells}{section.1.4}% 28
\BOOKMARK [2][-]{subsection.1.4.2}{Dysregulation of gene expression in psoriasis circulating immune cells}{section.1.4}% 29
\BOOKMARK [2][-]{subsection.1.4.3}{Correlation between changes in chromatin accessibility and gene expression}{section.1.4}% 30
\BOOKMARK [2][-]{subsection.1.4.4}{Trancriptomic profiles in lesional and uninvolved psoriatic epidermis}{section.1.4}% 31
\BOOKMARK [2][-]{subsection.1.4.5}{LncRNAs in psoriasis}{section.1.4}% 32
\BOOKMARK [2][-]{subsection.1.4.6}{Differences in transcriptional dysregulation in blood and skin}{section.1.4}% 33
\BOOKMARK [2][-]{subsection.1.4.7}{Fine-mapping and the chr2p15 locus}{section.1.4}% 34
\BOOKMARK [2][-]{subsection.1.4.8}{Limitations in the approach and future work}{section.1.4}% 35
\BOOKMARK [2][-]{subsection.1.4.9}{Conclusions}{section.1.4}% 36
\BOOKMARK [0][-]{subsection.1.4.9}{Appendices}{}% 37
\BOOKMARK [0][-]{appendix.A}{Tables}{}% 38
\BOOKMARK [1][-]{section.A.1}{Chapter 3 Tables}{appendix.A}% 39
\BOOKMARK [1][-]{section.A.2}{Chapter 4 Tables}{appendix.A}% 40
\BOOKMARK [1][-]{section.A.3}{Chapter 5 Tables}{appendix.A}% 41
\BOOKMARK [0][-]{appendix.B}{Additional figures}{}% 42
\BOOKMARK [1][-]{section.B.1}{Chapter 3 Figures}{appendix.B}% 43
\BOOKMARK [1][-]{section.B.2}{Chapter 4 Figures}{appendix.B}% 44
\BOOKMARK [1][-]{section.B.3}{Chapter 5 Figures}{appendix.B}% 45
\BOOKMARK [0][-]{appendix*.87}{Bibliography}{}% 46
